{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:43:39Z","timestamp":1789105419248,"version":"build-2803163510"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dutch ICC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Risankizumab, a monoclonal antibody targeting interleukin-23, is approved for the treatment of Crohn\u2019s disease (CD). Real-world evidence on its effectiveness remains limited. We assessed 1-year effectiveness and safety of risankizumab in a prospective cohort of patients with CD, emphasizing difficult-to-treat disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were retrieved from the Dutch Initiative on Crohn and Colitis Registry. At baseline and at weeks 12, 24, and 52, clinical remission (Harvey-Bradshaw Index\u2009\u22644), biochemical remission (fecal calprotectin\u2009\u2264250\u2009\u00b5g\/g and C-reactive protein levels\u2009\u22645\u2009mg\/L), systemic corticosteroids use, and safety outcomes were determined. The primary outcome was corticosteroid-free clinical remission (CSFCR) at week 24. Difficult-to-treat disease was defined as the failure of advanced therapies with at least 2 different mechanisms of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 151 patients initiated risankizumab before August 1, 2025; 136 (90.1%) of 151 patients had difficult-to-treat disease. At baseline, 90 (59.6%) patients had Harvey-Bradshaw Index \u2009&amp;gt;4. Of those, at week 24, 31 (50%) of 62 patients were in CSFCR; this rate was 53.3% when including all patients. Analysis including only patients with difficult-to-treat disease revealed that 51.8% of these patients were in CSFCR at week 24. Twenty-two (14.6%) patients discontinued treatment after a median of 183.5\u2009days (Q1-Q3: 90.0-295.2 days), most following nonresponse. Regarding adverse events, 35.3 possibly and 16.6 probably risankizumab-related events per 100 person-years were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this prospective multicenter study, risankizumab demonstrated favorable effectiveness and safety profile in patients with CD, including those with difficult-to-treat disease, bowel surgery, and stoma. These findings support the use of risankizumab in patients with difficult-to-treat disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag045","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:42:53Z","timestamp":1772196173000},"page":"1460-1470","source":"Crossref","is-referenced-by-count":1,"title":["Prospective real-world experience with risankizumab in difficult-to-treat Crohn\u2019s disease: results from the Dutch Initiative on Crohn and Colitis Registry"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6106-1470","authenticated-orcid":false,"given":"Loriane M M","family":"Verleye","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maastricht UMC+ , 6229 HX Maastricht,","place":["the Netherlands"]},{"name":"NUTRIM Institute for Nutrition and Translational Research in Metabolism, Maastricht University , 6229 ER Maastricht,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J","family":"Pierik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maastricht UMC+ , 6229 HX Maastricht,","place":["the Netherlands"]},{"name":"NUTRIM Institute for Nutrition and Translational Research in Metabolism, Maastricht University , 6229 ER Maastricht,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-9201","authenticated-orcid":false,"given":"Annemarie C","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center , 3015 GD Rotterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2451-1809","authenticated-orcid":false,"given":"Fiona D M","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Utrecht , 3584 CX Utrecht,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-5431","authenticated-orcid":false,"given":"Andrea E","family":"van der Meulen-de Jong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center , 2333 ZA Leiden,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6594","authenticated-orcid":false,"given":"Willemijn A","family":"van Dop","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboudumc , 6525 GA Nijmegen,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4975-9945","authenticated-orcid":false,"given":"Mark","family":"L\u00f6wenberg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam UMC , 1100 DD Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-7677","authenticated-orcid":false,"given":"Marijn C","family":"Visschedijk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen , 9713 GZ Groningen,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6546-3765","authenticated-orcid":false,"given":"Myrthe R","family":"Naber","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Utrecht , 3584 CX Utrecht,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6208-2967","authenticated-orcid":false,"given":"Dianne G","family":"Bouwknegt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen , 9713 GZ Groningen,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-9823","authenticated-orcid":false,"given":"Tessa E H","family":"R\u00f6mkens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital , 5223 GW 's-Hertogenbosch,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-9995","authenticated-orcid":false,"given":"Alexander G L","family":"Bodelier","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amphia Hospital , 4818 CK Breda,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-4435","authenticated-orcid":false,"given":"Philip W","family":"Voorneveld","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center , 2333 ZA Leiden,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3962-6831","authenticated-orcid":false,"given":"Bas","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Utrecht , 3584 CX Utrecht,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-8451","authenticated-orcid":false,"given":"Lauranne A A P","family":"Derikx","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center , 3015 GD Rotterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-9376","authenticated-orcid":false,"given":"Marjolijn","family":"Duijvestein","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboudumc , 6525 GA Nijmegen,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-0381","authenticated-orcid":false,"given":"Zlatan","family":"Mujagi\u0107","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maastricht UMC+ , 6229 HX Maastricht,","place":["the Netherlands"]},{"name":"NUTRIM Institute for Nutrition and Translational Research in Metabolism, Maastricht University , 6229 ER Maastricht,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Dutch Initiative on Crohn and Colitis (ICC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Willemen-Boemaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safioen","family":"Nabibaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Cosijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes H C","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindia","family":"Jharap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Bouwens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Jeuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Sour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Schlotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"van Workum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe","family":"Verwey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Meyboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jael","family":"Smid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herma H","family":"Fidder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke A","family":"Boontje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince","family":"Biemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Straatmijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"2026072823464360100_izag045-B1","doi-asserted-by":"publisher","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)","volume":"14","author":"Gargiulo","year":"2023","journal-title":"Front Immunol"},{"key":"2026072823464360100_izag045-B2","doi-asserted-by":"publisher","first-page":"2358150","DOI":"10.1080\/09546634.2024.2358150","article-title":"Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)","volume":"35","author":"Orsini","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026072823464360100_izag045-B3","doi-asserted-by":"publisher","first-page":"17562848251338743","DOI":"10.1177\/17562848251338743","article-title":"Clinical insights into IL-23 inhibition: risankizumab for Crohn\u2019s disease through a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Huang","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"2026072823464360100_izag045-B4","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003670","article-title":"Patients included in clinical trials of biological drugs for inflammatory bowel disease do not represent the real-world population","author":"Casas Deza","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026072823464360100_izag045-B5","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/ibd\/izad315","article-title":"Real-world effectiveness and safety of risankizumab in patients with moderate to severe multirefractory Crohn\u2019s disease: a belgian multicentric cohort study","volume":"30","author":"Alsoud","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026072823464360100_izag045-B6","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.cgh.2024.04.016","article-title":"Long-term outcome of risankizumab in Crohn\u2019s disease: a real-world GETAID study","volume":"22","author":"Fumery","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072823464360100_izag045-B7","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/ibd\/izae248","article-title":"The effectiveness of risankizumab as induction therapy for Crohn\u2019s disease: data from the sicilian network for inflammatory bowel diseases","volume":"31","author":"Macaluso","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026072823464360100_izag045-B8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/flgastro-2024-102809","article-title":"Effectiveness of risankizumab induction and maintenance therapy for refractory Crohn\u2019s disease: a real-world experience from a preapproval access programme and early access to medicines scheme","volume":"15","author":"Zare","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"2026072823464360100_izag045-B9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.cgh.2024.09.027","article-title":"Long-term effectiveness and safety of risankizumab in patients with Crohn\u2019s disease","volume":"23","author":"Zinger","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072823464360100_izag045-B10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/ecco-jcc\/jjab081","article-title":"Ustekinumab for Crohn\u2019s disease: two-year results of the initiative on Crohn and colitis (ICC) registry, a nationwide prospective observational cohort study","volume":"15","author":"Straatmijer","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026072823464360100_izag045-B11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S2468-1253(23)00154-1","article-title":"Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting","volume":"8","author":"Parigi","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072823464360100_izag045-B12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ueg2.12547","article-title":"Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment","volume":"12","author":"Caron","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2026072823464360100_izag045-B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1756283X14553384","article-title":"The role and utility of faecal markers in inflammatory bowel disease","volume":"8","author":"Lehmann","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"2026072823464360100_izag045-B14","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"2026072823464360100_izag045-B15","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/8\/1460\/67787030\/izag045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/8\/1460\/67787030\/izag045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:46:50Z","timestamp":1785296810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/8\/1460\/8586808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,4]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag045","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,4,4]]}}}